Corient Capital Partners’s Vaxart VXRT Stock Holding History

Corient Capital Partners’s Portfolio VXRT Stock Details VXRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-90,408	Closed	-$567K	–	772
2021 Q4	$567K	Buy	+90,408	New	+$617K	0.04%	346

Other funds holding VXRT

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Corient Capital Partners's VXRT Position: Q1 2022 in Review

Corient Capital Partners sold out of Vaxart (VXRT) in Q1 2022, closing a stake of 90,408 shares — an estimated $567K sold.

Corient Capital Partners first reported a position in VXRT in Q4 2021 and held it in 1 quarter. The position peaked at $567K in Q4 2021. 148 funds tracked by Wall St. Rank hold VXRT as of Q1 2022.

Corient Capital Partners reported no remaining Vaxart position as of Q1 2022 after selling out during the quarter.
Corient Capital Partners sold 90,408 Vaxart shares in Q1 2022, an estimated $567K.
Corient Capital Partners first reported a position in Vaxart in Q4 2021 and held it in 1 quarter.
Corient Capital Partners's Vaxart position peaked at $567K in Q4 2021.
148 funds tracked by Wall St. Rank held Vaxart as of Q1 2022.

Based on Corient Capital Partners's 13F filing for Q1 2022, filed 16 May 2022.